

Certolizumab in Recurrent Implantation Failure (RIF)

NCT05930613

Status	RECRUITING
Phase	Phase 3
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	161 participants

Key Eligibility Criteria

Inclusion (5)

- Women aged 18-40 years
- Idiopathic, male or tubal factor infertility
- Unexplained recurrent implantation failure defined as consecutive failure to obtain clinical pregnancy after at least transfers of 3 good-quality embryos (Istanbul criteria)
- Affiliation to a French social security system (beneficiary or legal)
- Informed and signed consent

Exclusion (35)

- Known cause of RIF among the following:
 - Genetic parental anomalies
 - Non-gestational diabetes mellitus of type I and II,
 - Infectious disease
 - Antiphospholipid syndrome
- ... and 30 more (see full listing online)

Locations (1 total)

Saint-Antoine Hospital - APHP, Paris, France